Co-Diagnostic Enters into Agreement with Arches Research to Expand COVID-19 Testing
September 11, 2020
Co-Diagnostics, a Salt Lake City company that was out of the gate early with a molecular COVID-19 test, announced this week that it has entered into an agreement with another Salt Lake City based company, Arches Research, a CLIA laboratory and subsidiary of PolarityTE to expand Arches’ COVID-19 testing services using Co-Diagnostics’ Logix Smart™ COVID-19 test kit.
Dwight Egan, CEO of Co-Diagnostics, remarked, “We are pleased to have this opportunity to further expand our relationship with one of our valued CLIA lab clients to help meet demand for COVID-19 testing. Arches has been an important customer in the ongoing battle against the coronavirus, and we expect this agreement will also create opportunities for sales of additional molecular diagnostic products in our development pipeline, including our upcoming Logix Smart Flu A/Flu B/COVID-19 test kit.”
“It is particularly notable when two BioUtah companies join forces to expand testing capacity for COVID-19 in Utah, which is critical to a safe reopening of our communities and economy,” added Kelvyn Cullimore, president and CEO of BioUtah.
Recent News
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
- Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
- Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology